Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 7:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,005 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Dose Escalation Clear all

Conditions: Asthma
Interventions: MEDI528 0.3 mg/kg, MEDI528 1 mg/kg, MEDI528 3 mg/kg, PLACEBO; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Denver, Colorado • North Dartmouth, Massachusetts • Minneapolis, Minnesota + 3 more

Conditions: Small Cell Lung Carcinoma
Interventions: LY2940680, Carboplatin, Etoposide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 12
States / cities: Fayetteville, Arkansas • Athens, Georgia • Las Vegas, Nevada + 8 more

Conditions: Myotonic Dystrophy Type 1 (DM1)
Interventions: VX-670, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: San Carlos, California • Gainesville, Florida • Fairway, Kansas + 5 more

Conditions: Systemic Lupus Erythematosus, Widespread Pain, Fibromyalgia
Interventions: Milnacipran; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: HCV Infection
Interventions: ACH-0137171; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Phoenix, Arizona • La Jolla, California • San Francisco, California + 4 more

Conditions: Human Immunodeficiency Virus
Interventions: TMB-607, Placebo; Drug
Lead sponsor: TaiMed Biologics Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma
Interventions: ASP2767, Sham ASP2767, Prophylactic Regimen A, Prophylactic Regimen B, Placebo for prophylactic regimen; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glaucoma, Ocular Hypertension, Eye Disease
Interventions: AMA0076, Placebo; Drug
Lead sponsor: Amakem, NV; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Artesia, California • Inglewood, California • Petaluma, California + 3 more

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-04603629, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 4
States / cities: Phoenix, Arizona • Miami, Florida • Wichita, Kansas + 1 more

Conditions: Epilepsy, Healthy Volunteer
Interventions: SIF001, Placebo; Biological · Drug
Lead sponsor: Suninflam Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: Tucson, Arizona • DeLand, Florida • Tamarac, Florida + 7 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: semaglutide, oral placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 632 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 40
States / cities: Tucson, Arizona • Chula Vista, California • Long Beach, California + 34 more

Conditions: Diabetes Mellitus Type 2
Interventions: Placebo, RO5095932; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions: Bifeprunox; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Orange, California

Conditions: Healthy
Interventions: ASC42, Placebo; Drug
Lead sponsor: Gannex Pharma Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hypertension
Interventions: Azilsartan medoxomil, Valsartan, Olmesartan, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 86
States / cities: Alabaster, Alabama • Ozark, Alabama • Green Valley, Arizona + 83 more

Conditions: Obesity and Overweight
Interventions: NA-931, Tirzepatide, NA-931 150 mg + no Tirzepatide; Drug
Lead sponsor: Biomed Industries, Inc.; Industry
Eligibility: 19 Years to 80 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 5 more

Conditions: HIV Infections
Interventions: BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted, Placebo; Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 51 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • New York, New York

Conditions: Botulism
Interventions: XOMA 3AB, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Rheumatoid Arthritis
Interventions: PDA001, Vehicle Controlled Placebo; Biological · Drug
Lead sponsor: Celularity Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 16
States / cities: Anniston, Alabama • Arcadia, California • Los Angeles, California + 12 more

Conditions: Ascites Hepatic
Interventions: OsrHSA 20 mg/kg IV, OsrHSA 40 mg/kg IV, OsrHSA 80 mg/kg IV, OsrHSA 140 mg/kg IV, OsrHSA 200 mg/kg IV, Placebo; Drug · Other
Lead sponsor: Healthgen Biotechnology Corp.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cypress, California

Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Interventions: INGAP-Peptide, placebo; Drug
Lead sponsor: Exsulin Corporation; Industry
Eligibility: 35 Years to 70 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 17
States / cities: La Jolla, California • San Diego, California • Walnut Creek, California + 13 more

Conditions: Heart Failure, Reduced Ejection Fraction
Interventions: sacubitril/valsartan (LCZ696), enalapril, matching placebo sacubitril/valsartan (LCZ696), matching placebo enalapril; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 23
States / cities: Fort Payne, Alabama • Beverly Hills, California • Stockton, California + 20 more

Conditions: Multiple Sclerosis
Interventions: dimethyl fumarate; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 15
States / cities: Gilbert, Arizona • Phoenix, Arizona • Long Beach, California + 12 more

Conditions: Healthy Participants
Interventions: BMS-986421, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cypress, California

Search by objective public record fields.

A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma

A Study of LY2940680 in Small Cell Lung Cancer

A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection

Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers

A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage

Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma

Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients

Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.

Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder

Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ASC42 in Healthy Subjects

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 Gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults

Phase 1 PK Study of XOMA 3AB

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis

A Study of OsrHSA in Adult Healthy Male and Female Volunteers

Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes

Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.

Tecfidera Slow-Titration Study

A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants